“On innovation as another catalyst, we are still committed to and expect approval of our dual-analyte system.”

In context

“patient advocacy. We showed in an RCT, which I talked about earlier, that patients on basal do better with Libre. There is so much opportunity still internationally and in the U.S. I do not think the patient TAM is tapped. You will have moments where growth modulates a little bit, and then the next catalysts come in and drive growth. You have to look at the bigger picture: you have 70 to 80 million people who can be on this product. Even if you look at a yearly revenue number that is lower than what we are seeing today because you have different types of patient groups, you are looking at a $3.035 trillion opportunity here that is available to us, and we are focused on that—focused on building competitive advantage, whether product technology advantage, cost advantage, or scale advantage. On innovation as another catalyst, we are still committed to and expect approval of our dual-analyte system. On the pump side, you have about 1 million patients that previously had very little access. You are going to have about 5 million SGLT2 users that are not using the product who will now benefit from having continuous ketone monitoring. We are working on Libre 5. Our view is always about sustaining our competitive advantage through cost advantage and product innovation. I still feel very good about this market. We look at weekly TRxs too, and we see the trends. There are areas we can do better, and we are working on that, but the bigger picture is that we are very well positioned for a very large market. Larry Biegelsen: Alright. Thanks so much. Operator: Thank you. Our next question will come from Vijay Kumar from Evercore ISI. Your line is open. Vijay Kumar: Hi, Robert. Good morning, and”